Oct 2026· Frontiers in Oncology· Vol 16· 0 citations· 28 references
TL;DR
In patients achieving ypN0, pre-treatment cN did not demonstrate statistically significant additional prognostic discrimination in this cohort, although estimates were imprecise due to the small cN+/ypN0 subgroup and limited events.
Abstract
Neoadjuvant chemoimmunotherapy (nCIT) has emerged as a standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the independent prognostic value of postoperative pathological N stage (ypN) and to assess whether pre-treatment clinical N stage (cN) provides additional prognostic information in patients achieving ypN0.
We retrospectively analyzed 194 ESCC patients who received nCIT followed by radical esophagectomy between January 2019 and December 2024. Patients were stratified into three groups: cN0/ypN0 (n=104), cN+/ypN0 (n=32), and ypN+ (n=58). Kaplan-Meier analysis and Cox proportional hazards models were used for survival analysis. Multivariable models were constructed using a clinically informed variable-selection strategy constrained by the number of events. For the three pairwise comparisons, unadjusted P values were compared against a Bonferroni-adjusted significance threshold of alpha=0.017 (0.05/3).
A total of 194 patients were enrolled, with 31 deaths and 37 recurrences during a median follow-up of 34.0 months (reverse Kaplan–Meier). ypN+ patients had significantly worse overall survival (OS) and recurrence-free survival (RFS) than ypN- patients (both Log-rank P<0.001). In the primary multivariable model, ypN+ was an independent adverse prognostic factor for OS (HR = 3.204, 95%CI: 1.563-6.568, P = 0.001) and RFS (HR = 3.780, 95%CI: 1.943-7.356, P<0.001), and remained robust across extended, cycle-adjusted, and landmark sensitivity analyses. Among the three groups, ypN+ showed significantly shorter OS compared with both ypN0 groups (P = 0.002 vs cN0/ypN0; P = 0.008 vs cN+/ypN0; both below the Bonferroni threshold) and shorter RFS compared with cN0/ypN0 (P<0.001). No significant difference was observed between cN0/ypN0 and cN+/ypN0 groups for OS (P = 0.259); the RFS comparison was nominally significant but did not survive Bonferroni correction (HR = 2.799, 95%CI: 1.048-7.479, unadjusted P = 0.040).
Postoperative ypN stage is the core prognostic determinant in ESCC after nCIT. In patients achieving ypN0, pre-treatment cN did not demonstrate statistically significant additional prognostic discrimination in this cohort, although estimates were imprecise due to the small cN+/ypN0 subgroup and limited events. Postoperative risk assessment should be based primarily on ypN status; these findings require validation in larger, preferably multicenter, cohorts.
Although PORT did not significantly improve survival in the overall cSCLN+ population, a trend toward improved OS was observed in the cSCLN+pSCLN+ subgroup, suggesting PORT may be considered as a potential strategy to improve survival outcomes.
Yi-Meng Yu, Lin Lin, Ya Zeng et al.· Annals of Surgical Oncology· 0 citations
BACKGROUND
In locally advanced esophageal squamous cell carcinoma (LA-ESCC), neoadjuvant chemoimmunotherapy (NCIT) plus high-quality surgery (R0 resection with systematic lymphadenectomy >19 nodes) is a promising strategy. However, the value of adjuvant immunotherapy remains unclear. This study aimed to evaluate the as...
Jing-Wei Sun, Pei-Long Bao, Yu-Quan Bai et al.· Journal of Thoracic and Card...· 0 citations
After additional adjustment for cT, cN, and cM, bulky status was no longer significantly associated with DFS or OS and did not improve model fit, but its incremental prognostic value beyond cTNM staging appears limited.
Guo-Qing Zhang, Kang-Hua Zhang, Chang Yuan et al.· Annals of Surgical Oncology· 1 citation
This study aimed to compare postoperative overall survival (OS) and cancer-specific survival (CSS) between neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced esophageal cancer using a real-world cohort. This retrospective study enrolled patients with primary esopha...
Jin Zhang, Yao-Hua Chen· Scientific Reports· 0 citations
While primary surgery remains a crucial treatment for resectable esophageal squamous cell carcinoma (ESCC), the uniform application of postoperative adjuvant chemotherapy for pathologically node-positive patients exposes many to severe systemic toxicity. This study hypothesizes the existence of a specific lymph nod...
Yi-Cheng Huang, Xuan-Hao Lin, Yan-Hong Lin et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.